Ultromics Becomes a Founding Partner of the National Consortium of Intelligent Medical Imaging to develop AI-based diagnostic ecosystem
- £50m Innovate UK funding programme announced to realise the government’s Life Sciences strategy – and improve NHS diagnostics
- Ultromics has developed the first outcomes-driven, AI-based ultrasound diagnostic support tool for coronary artery disease
- Startup to form part of a consortium designed to enhance diagnostic services
Ultromics, the UK startup driving innovation in coronary artery disease (CAD) diagnostics,will help the National Consortium of Intelligent Medical Imaging (NCIMI) as part of a government-led initiative to improve diagnostic services and establish a network of digital pathology, imaging, and AI centres. Led from Oxford University and including a range of NHS Trusts, industry partners, and SMEs from across the country, the consortium will receive £10 million of investment from Innovate UK as part of the Industrial Strategy Challenge fund – with a further £5 million coming from commercial partners.
“I’m delighted to be contributing to the efforts of this consortium”, said Ross Upton, CEO and Academic Founder of Ultromics. “We’ve always believed that AI could make a real impact on patient outcomes. Through our own work, and our work with NCIMI, we intend to prove it.”
NCIMI aims to provide tangible results for patients by using AI in medical imaging across MRI, CT, PET, X-Ray, and ultrasound. The consortium also intends to develop a sustainable platform for further innovations – as well as a framework for future NHS adoption of AI-based technologies. Ultromics’ work, which uses AI to facilitate early detection of cardiovascular disease, will contribute to these objectives as part of a new pipeline of algorithms designed to benefit NHS patients.
Professor Gavin Screaton, Head of the University of Oxford Medical Sciences Division said “We are delighted that Innovate UK has chosen to support our National Consortium. We believe that combining the heath data, ethics, clinical and AI expertise within the University with a national NHS network and a range of industry partners has real potential to introduce new solutions which will improve patient care”.
UK Research and Innovation Chief Executive Professor Sir Mark Walport said: “Early diagnosis of illness can greatly increase the chances of successful treatment and save lives”.
“The centres announced today bring together the teams that will develop artificial intelligence tools that can analyse medical images varying from x-rays to microscopic sections from tissue biopsies. Artificial intelligence has the potential to revolutionise the speed and accuracy of medical diagnosis.”
Ultromics develops echo-based diagnostic support tools for cardiovascular disease, the largest cause of death globally, by combining deep clinical insight with machine learning and some of the largest echo datasets in the world. Our revolutionary tools help doctors make consistent and accurate diagnoses, without disrupting clinical workflow, to ensure patients are not sent for unnecessary surgical procedures or sent home with potentially fatal disease.